Scholar Rock Holding SRRK
NASDAQ SRRK
$55.13 -0.81 (-1.45%)
As of: Sep 4, 2026 · 1:39 PM EDT

Scholar Rock Holding (SRRK) Cash from Investing Activities (2017 - 2026)

Scholar Rock Holding (SRRK) posted quarterly Cash from Investing Activities of -$5.3 million for Q1 2026, down 115.44% year-over-year from $34.6 million in Q1 2025, and down 113.69% quarter-over-quarter from $39.0 million in Q4 2025.

Analysis

Scholar Rock Holding (SRRK) Cash from Investing Activities (2017 - 2026) Analysis & Trends

Scholar Rock Holding's Cash from Investing Activities history runs 10 years deep, the most recent figure standing at -$5.3 million for Q1 2026.

  • In Q1 2026, Cash from Investing Activities fell 115.44% year-over-year to -$5.3 million; the TTM figure through Mar 2026 stood at $178.8 million (up 338.76% YoY), while the FY2025 annual figure was $218.7 million, up 387.53% from the prior year.
  • Cash from Investing Activities for Q1 2026 stood at -$5.3 million, down from $39.0 million in the prior quarter.
  • The five-year high for Cash from Investing Activities was $90.0 million in Q1 2023, with the low at -$195.4 million in Q4 2024.
  • The 5-year median for Cash from Investing Activities is $33.4 million (2024), against an average of $396411.8.
  • The sharpest annual moves came in 2023 and 2024: Cash from Investing Activities slumped 32733.77% in 2023, then jumped 516.71% in 2024.
  • Scholar Rock Holding's Cash from Investing Activities stood at $77000.0 in 2022, then plunged by 32733.77% to -$25.1 million in 2023, then sank by 677.5% to -$195.4 million in 2024, then surged by 119.95% to $39.0 million in 2025, then sank by 113.69% to -$5.3 million in 2026.
  • Business Quant data shows SRRK's Cash from Investing Activities at -$5.3 million in Q1 2026, $39.0 million in Q4 2025, and $59.7 million in Q3 2025.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cash from Investing Activities (Qtr)
1 Vertex Pharmaceuticals 139.31 Bn 131.46 Bn 2.84 Bn -45.80 Mn
2 Regeneron Pharmaceuticals 85.65 Bn 77.66 Bn 3.93 Bn -92.70 Mn
3 Argenx Se 63.46 Bn 58.27 Bn 1.37 Bn -
4 Moderna 57.94 Bn 52.80 Bn 52.00 Mn 329.00 Mn
5 Revolution Medicines 44.05 Bn 44.05 Bn - -1.66 Bn
6 BeOne Medicines 39.96 Bn 34.86 Bn 1.53 Bn -49.35 Mn
7 Alnylam Pharmaceuticals 35.16 Bn 31.85 Bn 992.69 Mn -363.46 Mn
8 Royalty Pharma 28.44 Bn 27.60 Bn - -229.72 Mn
9 Insmed 27.32 Bn 26.16 Bn 358.27 Mn 24.51 Mn
10 Scholar Rock Holding 7.19 Bn 7.19 Bn - -5.50 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 -5.50 Mn
Mar 31, 2026 -5.34 Mn
Dec 31, 2025 38.97 Mn
Sep 30, 2025 59.70 Mn
Jun 30, 2025 85.47 Mn
Mar 31, 2025 34.55 Mn
Dec 31, 2024 -195.37 Mn
Sep 30, 2024 35.31 Mn
Jun 30, 2024 50.62 Mn
Mar 31, 2024 33.38 Mn
Dec 31, 2023 -25.13 Mn
Sep 30, 2023 -8.47 Mn
Jun 30, 2023 -15.24 Mn
Mar 31, 2023 89.98 Mn
Dec 31, 2022 77,000.00
Sep 30, 2022 -145.72 Mn
Jun 30, 2022 44.52 Mn
Mar 31, 2022 -70.58 Mn
Dec 31, 2021 29.46 Mn
Sep 30, 2021 3.28 Mn